<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although c-myc is classically described as the driving oncogene in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), deregulation and mutations of c-myc have been reported in multiple <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> and in other mature B cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> such as mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), <z:mp ids='MP_0009440'>myeloma</z:mp>, and plasma cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:chebi fb="43" ids="53200">PCL</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>After translocation into the IgH locus, c-myc is constitutively expressed under the control of active IgH enhancers </plain></SENT>
<SENT sid="2" pm="."><plain>Those located in the IgH 3' regulatory region (3'RR) are master control elements of class switch recombination and of the transcriptional burst associated with plasma cell differentiation </plain></SENT>
<SENT sid="3" pm="."><plain>c-myc-3'RR mice are prone to <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with rather homogeneous, most often <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-like, phenotypes with <z:hpo ids='HP_0003829'>incomplete penetrance</z:hpo> (75% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> incidence) and long latencies (10-12 mo) </plain></SENT>
<SENT sid="4" pm="."><plain>To reproduce c-myc-induced mature B cell <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> in the context of an additional defect often observed in human <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, we intercrossed c-myc-3'RR with p53(+/-) mice </plain></SENT>
<SENT sid="5" pm="."><plain>Double transgenic c-myc-3'RR/p53(+/-) mice developed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with short latency (2-4 mo) and full penetrance (100% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> incidence) </plain></SENT>
<SENT sid="6" pm="."><plain>The spectrum of B <z:hpo ids='HP_0002665'>lymphomas</z:hpo> occurring in c-myc-3'RR/p53(+/-) mice was widened, including nonactivated (CD43(-)) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, activated (CD43(+)) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-like <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:chebi fb="43" ids="53200">PCL</z:chebi>, thus showing that 3'RR-mediated deregulation of c-myc can promote various types of B lymphoproliferation in cells that first acquired a p53 defect </plain></SENT>
<SENT sid="7" pm="."><plain>c-myc/p53(+/-) mice closely reproduce many features of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, and <z:chebi fb="43" ids="53200">PCL</z:chebi> and provide a novel and efficient model to dissect the molecular events leading to c-myc-induced <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> and an important tool to test potential therapeutic agents on malignant B cells featuring various maturation stages </plain></SENT>
</text></document>